GPCR
$56.15
Structure Therapeutics Inc., a clinical stage global biopharmaceutical company, develops and delivers novel oral small molecule therapeutics to treat various chronic diseases with unmet medical needs in the United States.
Intraday
Recent News
Rival GLP-1 pill matches Wegovy weight loss data, adding to competitive pressure on Novo Nordisk
Citi has kept its 'neutral' rating on Novo Nordisk (NYSE:NVO) after a rival company released clinical data showing its oral GLP-1 drug delivered weight loss broadly comparable to Novo's own obesity pill, adding to a growing list of competitive threats facing the Danish pharmaceutical...
These Stocks Are Today’s Movers: Nvidia, Nebius, Meta, Micron, Strategy, Structure Therapeutics, Dollar Tree, and More
Stocks rose Monday as oil prices fell and President Donald Trump called on other countries to join the U.S. in ensuring safe passage through the Strait of Hormuz. Nvidia boss Jensen Huang touted the widespread adoption of Nvidia’s CUDA platform over the past two decades. The memory-chip maker said it plans to build a second manufacturing facility at its site in Taiwan by the end of 2026.
Structure Therapeutics Pops; But Can It Take On Lilly's Looming Obesity Pill?
Structure Therapeutics shares surged Monday after the biotech said its daily pill helped patients lose up to 39 pounds over a 44-week study.
A New GLP-1 Pill Melted Away the Pounds. Is Structure Therapeutics a Takeover Candidate?
Structure Therapeutics said its GLP-1 pill helped patients lose more than 16% of their body weight in a midstage trial, outperforming results reported for competing obesity drugs.
Structure Therapeutics Says Aleniglipron Reduces Weight in Phase 2, Extension Studies
Structure Therapeutics (GPCR) said Monday that its aleniglipron clinical program to potentially trea